Clinical Trials Logo

Migraine Disorders clinical trials

View clinical trials related to Migraine Disorders.

Filter by:

NCT ID: NCT02163993 Completed - Migraine Headache Clinical Trials

A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache

Start date: July 7, 2014
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to evaluate whether the study drug known as galcanezumab is safe and effective in the prevention of migraine headaches.

NCT ID: NCT02159547 Completed - Migraine Clinical Trials

IV Dexketoprofen vs Placebo in Migranie Attack

Start date: May 2014
Phase: Phase 4
Study type: Interventional

H0 hypothesis: IV dexketoprofen is equivalent to placebo in ceasing migraine attack in emergency department. H1 hypothesis: IV dexketoprofen is not equivalent (superior) to placebo in ceasing migraine attack in emergency department.

NCT ID: NCT02158221 Completed - Clinical trials for Migraine Without Aura

PACAP Induced Migraine Attacks in Patients With High and Low Genetic Load

Start date: June 2014
Phase: N/A
Study type: Interventional

The investigators hypothesized that migraine without patients with many genetic loci associated with migraine (high genetic load) would be more sensitive and get provoked more migraine attacks by PACAP compared to patients with few genetic loci associated with migraine (low genetic load).

NCT ID: NCT02147561 Completed - Migraine Disorders Clinical Trials

A Safety and Efficacy Study of BOTOX® in Korean Adults With Chronic Migraine

Start date: July 2014
Phase: Phase 4
Study type: Interventional

This study will evaluate the safety and efficacy of BOTOX® treatment in Korean adults with chronic migraine.

NCT ID: NCT02133209 Completed - Migraine Clinical Trials

MRI Outcomes of Mindfulness Meditation for Migraine

Start date: May 2014
Phase: N/A
Study type: Interventional

112 migraine subjects will be initially randomly assigned to Mindfulness-Based Stress Reduction (MBSR) or a Stress Management for Headache group (SMH). Outcomes, including headache frequency and impact and brain activity, will be assessed at baseline, prior to intervention, and at 3-, 6-, and 12-months.

NCT ID: NCT02132429 Terminated - Migraine Clinical Trials

Phase I, Double-Blind,Placebo, MAD Study to Evaluate the Safety, Tolerability, PK, and PD of AMG 333 in Healthy Subjects and Migraine Subjects

Start date: May 2014
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to evaluate the safety and tolerability of multiple oral doses of AMG 333 for 14 days in healthy subjects and migraine subjects. As part of the secondary objectives, the study will characterize the pharmacokinetic (PK) profile of AMG 333 after multiple oral doses in healthy subjects and migraine subjects, as well as characterize the effect of multiple doses of AMG 333 on increases in blood pressure (BP) induced by the cold pressor test (CPT) in healthy subjects.

NCT ID: NCT02127294 Completed - Migraine Clinical Trials

Effectiveness and Safety of Transcatheter Patent Foramen Ovale Closure for Migraine

EASTFORM
Start date: January 2013
Phase: N/A
Study type: Interventional

The purpose of the study is to evaluate effectiveness and safety of transcatheter patent foramen ovale closure for migraine.

NCT ID: NCT02122757 Withdrawn - Sporadic Migraine Clinical Trials

Anodal Transcranial Direct Current Stimulation of the Visual Cortex Versus Sham Stimulation in the Episodic Migraine

ANODEM
Start date: September 2013
Phase: N/A
Study type: Interventional

Anodal tDCS increases the excitability of the cerebral cortex and its daily application during intercritical phase, may have a therapeutic effect in episodic migraine.

NCT ID: NCT02122744 Withdrawn - Chronic Migraine Clinical Trials

RCT Versus Placebo of rTMSQP Over Visual Cortex for the Prevention of Chronic Migraine

Start date: September 2013
Phase: N/A
Study type: Interventional

Evaluation of inhibiting rTMS QP over the visual cortex for the prevention of chronic migraine. The aim of the study is to confirm that inhibiting rTMS QP is capable to decrease the frequency of migraine and if its effect is stronger than placebo effect.

NCT ID: NCT02122237 Completed - Chronic Migraine Clinical Trials

Cathodal tDCS in Chronic Migraine: Neurophysiological Study and Pilot Therapeutic Trial

CATCHROMIG
Start date: September 2013
Phase: Phase 3
Study type: Interventional

Cathodal tDCS decreases the excitability of the cerebral cortex and its daily application during intercritical phase, may have a therapeutic effect in chronic migraine.